Author:
Chau Diane L.,Goldstein-Fuchs Jordi,Edelman Steven V.
Abstract
Although osteoporosis is the most prevalent metabolic bone disease in the United States, its impact in a people with diabetes is not often considered. Routine screening or initiation of preventive medications for osteoporosis in all patients with type 1 or type 2 diabetes is not recommended at this time. However, all patients with diabetes, and particularly those with fractures, should be given general recommendations regarding adequate dietary calcium intake, regular exercise, and avoidance of other potential risk factors. Consideration of bone density evaluation should be part of the fracture evaluation, and respective preventive or therapeutic interventions should be applied.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference25 articles.
1. World Health Organization: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. Geneva, World Health Org., 1994 (Tech. Rep. Ser., no. 843)
2. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL: Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 10:796–802, 1995
3. Wu F, Mason B, Horne A, Ames R, Clearwater J, Liu M, Evans MC, Gamble GD, Reid IR: Fractures between the ages of 20 and 50 years increase women’s risk of subsequent fractures. Arch Intern Med 162:33–36, 2002
4. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920–925, 1999
5. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192– 1197, 2001
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献